BlackRock, Inc. 13D and 13G filings for Arcutis Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 9,029,624 7.700% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 9,029,624 7.700% | 3,113,078 (+52.62%) | Filing |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 5,916,546 6.300% | 2,036,144 (+52.47%) | Filing |
| 2023-11-07 3:33 pm Sale | 2023-10-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 3,880,402 4.100% | -1,333,856 (-25.58%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 5,214,258 8.600% | 900,394 (+20.87%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 4,313,864 8.600% | 1,418,810 (+49.01%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 2,895,054 6.600% | 2,895,054 (New Position) | Filing |